Radiopharma Operations Are Fundamentally Different
In conventional pharmaceutical manufacturing, you make the product, test it, release it, and ship it. In radiopharmaceuticals, you are racing against physics.
A product made with Fluorine-18 has a half-life of 110 minutes. Lutetium-177 gives you 6.7 days. Actinium-225 gives you 10 days. Every hour of delay in manufacturing, quality control, or logistics destroys product. The COO must build operations that are time-critical in a way that no other pharmaceutical modality demands.
The Dual Regulatory Burden
The radiopharma COO must navigate two separate regulatory frameworks simultaneously. Pharmaceutical regulation (FDA, EMA) governs the drug product. Nuclear regulation (NRC in the US, national authorities in Europe) governs the radioactive materials.
These frameworks have different inspection cadences, different reporting requirements, and different compliance cultures. A COO who has only operated under pharmaceutical regulation will be overwhelmed. A COO from nuclear energy but not pharmaceuticals will lack the GMP foundation. The ideal candidate has experience with both.
Compensation at the Top
COO compensation in radiopharma ranges from $320,000 to $450,000 base in the US with total compensation of $450,000 to $700,000+ depending on company stage and equity. For earlier-stage companies, equity can represent 40-60% of total compensation.
The Infrastructure Question
Many radiopharma companies are simultaneously building physical infrastructure (hot cell facilities, isotope supply chains, radiopharmacy networks) while also building organisational infrastructure (quality systems, supply chain processes, regulatory capabilities).
The COO must be comfortable operating in an environment where foundational systems do not yet exist. This requires a leader who is comfortable with ambiguity, can make decisions with incomplete information, and can build teams in a high-growth, high-uncertainty environment.